Value of the lung immune prognostic index in patients with non‐small cell lung cancer initiating first‐line atezolizumab combination therapy: Subgroup analysis of the impower150 trial

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)
33 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Value of the lung immune prognostic index in patients with non‐small cell lung cancer initiating first‐line atezolizumab combination therapy: Subgroup analysis of the impower150 trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology